BNGO
Bionano Genomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.73
−0.57%Sep 14, 2026, 13:00 UTC
Three new peer-reviewed studies from independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute demonstrated the clinical value of Bionano's optical genome mapping in myelodysplastic syndromes and acute myeloid leukemia.
Source:Sep 8, 2026, 13:00 UTC
Bionano Laboratories received approval from the New York State Department of Health for its optical genome mapping-based lab developed tests, enabling clinical use at University of Rochester Medicine.
Source:Aug 10, 2026, 22:38 UTC
Bionano Genomics, Inc. held its Q2 2026 earnings call on August 10, 2026.
Source:Jun 24, 2026, 12:30 UTC
Bionano Genomics appointed Alex Hastie as Chief Scientific Officer, effective July 20, 2026.
Source:Jun 5, 2026, 00:00 UTC
Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc., effective July 5, 2026.